Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

AIMS: High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP) inhibitor torcetrapib raised blood pressure (BP), impa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Lüscher, Thomas F., Taddei, Stefano, Kaski, Juan-Carlos, Jukema, J. Wouter, Kallend, David, Münzel, Thomas, Kastelein, John J.P., Deanfield, John E.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2012
Teme:
Fasttrack Clinical
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3345558/
https://ncbi.nlm.nih.gov/pubmed/22345126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehs019
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki